한글목차

GVD(Global Value Dossier) 작성을 강화하기 위해 생성형 AI를 고려하는 제약사가 늘어남에 따라, 워크플로우를 간소화하고, 증거를 통합하며, 시장 진입 전략을 최적화할 수 있는 잠재력이 드러나고 있습니다.

AI가 이 프로세스에 어떤 변화를 가져올지 이해하기 위해 FirstWord는 S3 Connected Health의 컨설팅 서비스 프로그램 매니저인 Hany Mina를 만나 이야기를 나눴습니다.

보고서 내용

• 현재 GVD 생성에 있어 생성형 AI는 어떻게 활용되고 있는가?
• 기존 접근 방식과 비교하여 생성형 AI가 GVD 생성 프로세스에 어떤 고유한 이점을 제공하는가?
• GVD를 담당하는 메디컬 라이팅 팀과 마켓 액세스 팀에서 생성형 AI가 워크플로우를 혁신할 수 있을까?
• 가치 서술, 임상 요약, 경제 모델링 데이터 등 GVD의 핵심 컨텐츠 제작에 있어 생성형 AI가 얼마나 효과적인가?
• 생성형 AI가 특정 시장과 독자를 위해 GVD를 맞춤화하는 데 도움이 되는가?
• GVD 개발에 생성형 AI를 사용했을 때, 어떤 시간 및 비용 절감 효과를 보았는가?
• GVD에서 데이터의 정확성을 확보하는 것은 매우 중요하지만, 생성형 AI의 출력을 검증하기 위해 어떤 조치가 필요한가?
• 다양한 이해관계자를 위해 GVD의 내용을 조정하기 위해 생성형 AI를 어떻게 활용할 수 있는가?
• GVD 생성을 지원하기 위해 식별된 데이터 소스만 연결되고 올바른 데이터가 소비되도록 생성형 AI에 대한 데이터 입력을 어떻게 제어할 수 있는가?
• 특히 규제가 까다로운 시장에서 GVD의 엄격한 규제 기준을 충족하기 위해 생성형 AI를 어떻게 최적화할 수 있는가?
• 향후 5년 동안 GVD 생성에 가장 큰 영향을 미칠 것으로 예상되는 생성형 AI의 혁신은 무엇인가?
• GVD 생성에 있어 생성형 AI의 전체적인 그림을 생각했을 때, 추가적으로 추천하는 모듈이나 솔루션이 있는가?
• GVD 개발을 위해 생성형 AI를 막 고려하기 시작한 기업에게 어떤 조언을 해줄 수 있을까?

영문목차

As pharmas increasingly explore genAI to enhance global value dossier (GVD) creation, its potential to streamline workflows, synthesise evidence and optimise market access strategies is becoming more apparent.

To understand how AI is transforming this process, FirstWord spoke with Hany Mina, consulting services program manager at S3 Connected Health.

Key Questions Answered:

• How is genAI currently being used in GVD creation?
• What unique advantages does genAI bring to the process of creating GVDs compared with traditional approaches?
• Do you see genAI transforming workflows within the medical writing and market access teams responsible for GVDs?
• How effective is genAI in generating core GVD content, such as value narratives, clinical summaries and economic modelling data?
• Can genAI assist in tailoring GVDs for specific markets or audiences?
• What kind of time and cost-savings have you observed when using genAI for GVD development?
• Ensuring data accuracy is critical in a GVD. What measures are necessary to validate outputs from genAI?
• How can genAI be leveraged to tailor GVD content for different stakeholders?
• How can we control the data input to genAI to ensure only identified data sources are connected and correct data are consumed to support GVD generation?
• How can genAI be optimised to meet stringent regulatory standards in GVDs, especially in highly regulated markets?
• What innovations in genAI do you foresee having the biggest impact on GVD creation in the next five years?
• Thinking of the big picture for genAI in GVD creation, are there other modules or solutions you suggest adding?
• What advice would you give to companies just beginning to explore genAI for GVD development?

Methodology

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.